BPC
KYMR icon

Banque Pictet & Cie’s Kymera Therapeutics KYMR Stock Holding History

Banque Pictet & Cie’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,031
Closed -$545K – 637
2022
Q3 		$545K Sell
25,031
-94
-0.4% -$2.48K 0.01% 489
2022
Q2 		$495K Sell
25,125
-2,418
-9% -$56.5K ﹤0.01% 519
2022
Q1 		$1.17M Buy
+27,543
New +$1.16M 0.01% 422

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Banque Pictet & Cie's KYMR Position: Q4 2022 in Review

Banque Pictet & Cie sold out of Kymera Therapeutics (KYMR) in Q4 2022, closing a stake of 25,031 shares — an estimated $545K sold.

Banque Pictet & Cie first reported a position in KYMR in Q1 2022 and held it in 3 quarters. The position peaked at $1.17M in Q1 2022. 120 funds tracked by Wall St. Rank hold KYMR as of Q4 2022.

  • Banque Pictet & Cie reported no remaining Kymera Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Banque Pictet & Cie sold 25,031 Kymera Therapeutics shares in Q4 2022, an estimated $545K.
  • Banque Pictet & Cie first reported a position in Kymera Therapeutics in Q1 2022 and held it in 3 quarters.
  • Banque Pictet & Cie's Kymera Therapeutics position peaked at $1.17M in Q1 2022.
  • 120 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2022.

Based on Banque Pictet & Cie's 13F filing for Q4 2022, filed 6 Feb 2023.